MOORE JOHN R
Known title: General CounselCIK: 0001191702
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 6,718 | $0 | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,439 | $107K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 59 | $3K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 99 | $4K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,419 | $106K | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,098 | $28K | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,930 | $32K | 5/2/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,209 | $0 | 5/1/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 20,922 | $15K | 9/23/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 20,922 | $578K | 9/23/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 50,000 | $36K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 50,000 | $1.4M | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,956 | $37K | 5/2/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 8,029 | $15K | 2/9/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,029 | $161K | 2/9/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 3,813 | $7K | 2/8/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,813 | $76K | 2/8/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 17,993 | $35K | 2/7/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 17,993 | $360K | 2/7/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,497 | $89K | 12/27/2023 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,897 | $17K | 5/2/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,730 | $9K | 10/3/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,730 | $46K | 10/3/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,730 | $9K | 9/6/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,379 | $26K | 9/6/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,351 | $26K | 9/6/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,730 | $9K | 8/3/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,502 | $3K | 8/3/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 9,232 | $86K | 8/3/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 1,046 | $2K | 7/6/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,046 | $9K | 7/6/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 3,684 | $7K | 7/5/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,502 | $3K | 7/5/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,186 | $68K | 7/5/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 13,508 | $10K | 6/21/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 17,570 | $34K | 6/21/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 31,078 | $227K | 6/21/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 22,127 | $43K | 6/17/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 22,127 | $146K | 6/17/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 14,722 | $28K | 6/16/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 14,722 | $91K | 6/16/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 18,075 | $13K | 6/15/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 585 | $1K | 6/15/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 585 | $4K | 6/15/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 18,075 | $110K | 6/15/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 3,628 | $3K | 6/14/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,628 | $22K | 6/14/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,093 | $3K | 6/13/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,093 | $25K | 6/13/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 7,125 | $5K | 6/10/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 7,125 | $43K | 6/10/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 7,615 | $5K | 6/9/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 7,615 | $49K | 6/9/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 12,566 | $9K | 6/8/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 12,566 | $83K | 6/8/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 973 | $2K | 6/7/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 973 | $6K | 6/7/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 17,150 | $12K | 6/7/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 17,150 | $113K | 6/7/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 13,934 | $27K | 6/6/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 13,934 | $84K | 6/6/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 15,230 | $29K | 6/3/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 15,230 | $92K | 6/3/2022 | View on chart |
| EWTX | ▼ Sell | Open Market | 10,800 | $80K | 5/16/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,400 | $4K | 1/21/2022 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,400 | $4K | 12/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.